

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/560,303	03/29/2007	Masayori Inouye	601-1-131PCTUS	9634
23565 7590 12/08/2009 KLAUBER & JACKSON 411 HACKENSACK AVENUE			EXAMINER	
			HIBBERT, CATHERINE 8	
HACKENSACK, NJ 07601			ART UNIT	PAPER NUMBER
			1636	
			MAIL DATE	DELIVERY MODE
			12/08/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application/Control Number: 10/560,303

Art Unit: 1636

Attachment: Sequence Compliance

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below and/or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, Figures 1B, 9, 15, 20, 21, 28-35, and 39-42 contain sequences that are not identified by sequence identifier numbers. In addition, Table 2, page 108 of the specification, contains sequences that are not identified by sequence identifier numbers. If the sequences can be found in the sequence listing it would be remedial to insert the appropriate SEQ ID NO:s. If not, a substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification, CRF and letter stating that the contents of the sequence listing and the CRF are the same and contain no new matter is required.